Lithium: Still a cornerstone in the long-term treatment in bipolar disorder?

Neuropsychobiology

Volumn 62, Issue 1, 2010, Pages 27-35

  Nivoli, Alessandra M A ^a,b   Murru, Andrea ^a   Vieta, Eduard ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF SASSARI   (Italy)

Author keywords

Bipolar disorder, long term treatment; Lithium; Lithium prophylaxis

Indexed keywords

CARBAMAZEPINE; LAMOTRIGINE; LITHIUM SALT; OLANZAPINE; PLACEBO; VALPROATE SEMISODIUM; LITHIUM DERIVATIVE; TRANQUILIZER;

AKATHISIA; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; BIPOLAR MANIA; CLINICAL TRIAL; COGNITIVE THERAPY; CREATININE BLOOD LEVEL; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; ELECTROCONVULSIVE THERAPY; ENURESIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERSOMNIA; HYPERURICEMIA; HYPOMANIA; INFECTION; LEUKOCYTOSIS; LONG TERM CARE; LOW DRUG DOSE; MIXED MANIA AND DEPRESSION; MONOTHERAPY; NAUSEA; POLYDIPSIA; POLYURIA; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; TACHYCARDIA; TINNITUS; TREATMENT OUTCOME; TREMOR; VOMITING; XEROPHTHALMIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); TIME;

ANTIMANIC AGENTS; BIPOLAR DISORDER; HUMANS; LITHIUM COMPOUNDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS;

EID: 77951949829     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000314307     Document Type: Review

References (41)

1. Jefferson JW, Greist JH: Lithium; in Sadock BJ, Sadock VA (eds): Comprehensive Textbook of Psychiatry, ed 8. Philadelphia, Lippincott Williams & Wilkins, 2005, vol 2, pp 2839-2851.
2. Bech P: The full story of lithium. A tribute to Mogens Schou (1918-2005). Psychother Psychosom 2006; 75: 265-269.
3. Cade J: The story of lithium; in Ayd F, Blackwell B (eds): Discoveries in Biological Psychiatry. Philadelphia, Lippincott, 1970.
4. Schou M, Juel-Nielsen N, Stromgren E, Voldby H: The treatment of manic psychoses by the administration of lithium salts. J Neurol Neurosurg Psychiatry 1954; 17: 250-260.
5. Jope RS: Antibipolar therapy: mechanism of action of lithium. Mol Psychiatry 1999; 4: 117-128.
6. Manji HK, Potter WZ, Lenox RH: Signal transduction pathways. Arch Gen Psychiatry 1995; 52: 531-543.
7. Vieta E, Nolen WA, Grunze H, Licht RW, Goodwin G: A European perspective on the Canadian guidelines for bipolar disorder. Bipolar Disord 2005; 7(suppl 3):73-76.
8. Wu RH, O'Donnell T, Ulrich M, Asghar SJ, Hanstock CC, Silverstone PH: Brain choline concentrations may not be altered in euthymic bipolar disorder patients chronically treated with either lithium or sodium valproate. Ann Gen Hosp Psychiatry 2004; 3: 13.
9. Serretti A: Lithium long-term treatment in mood disorders: clinical and genetic predictors. Pharmacogenomics 2002; 3: 117-129.
10. Ikonomov OC, Manji HK: Molecular mechanisms underlying mood stabilization in manic-depressive illness: the phenotype challenge. Am J Psychiatry 1999; 156: 1506-1514.
11. El-Mallakh S: Litihum: Actions and Mechanisms. Washington, American Psychiatric Press, 1996.
12. Manji HK, Bowden CL, Belmaker RH: Bipolar Medication. Mechanisms of Action. Washington, American Psychiatry Press, 1999.
13. Goodwin GM: Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2003; 17: 149-173; discussion 147.
14. Grunze H, Kasper S, Goodwin G, Bowden C, Baldwin D, Licht R, Vieta E, Möller HJ, World Federation of Societies of Biological Psychiatry Task Force on Treatment Guidelines for Bipolar Disorders: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. 1. Treatment of bipolar depression. World J Biol Psychiatry 2002; 3: 115-124.
15. Yatham LN, Kennedy SH, O'Donovan C, Parikh SV, MacQueen G, McIntyre RS, Sharma V, Beaulieu S, Guidelines Group, CANMAT: Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord 2006; 8: 721-739.
16. Hirschfeld RM, Montgomery SA, Aguglia E, Amore M, Delgado PL, Gastpar M, Hawley C, Kasper S, Linden M, Massana J, Mendlewicz J, Möller HJ, Nemeroff CB, Saiz J, Such P, Torta R, Versiani M: Partial response and nonresponse to antidepressant therapy: current approaches and treatment options J Clin Psychiatry 2002; 63: 826-837.
17. Tondo L, Hennen J, Baldessarini RJ: Lower suicide risk with long-term lithium treatment in major affective illness: a metaanalysis. Acta Psychiatr Scand 2001; 104: 163-172.
18. Moncrieff J: Lithium revisited. A re-examination of the placebo-controlled trials of lithium prophylaxis in manic-depressive disorder. Br J Psychiatry 1995; 167: 569-574.
19. Geddes JR, Burgess S, Hawton K, Jamison K, Goodwin GM: Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry 2004; 161: 217-222.
20. Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A, Petty F, Pope HG Jr, Chou JC, Keck PE Jr, Rhodes LJ, Swann AC, Hirschfeld RM, Wozniak PJ: A randomized, placebocontrolled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000; 57: 481-489.
21. Bowden CL, Calabrese JR, Sachs G, Yatham LN, Asghar SA, Hompland M, Montgomery P, Earl N, Smoot TM, DeVeaugh-Geiss J, Lamictal 606 Study Group: A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003; 60: 392- 400. (Pubitemid 36403000)
22. Erratum in: Arch Gen Psychiatry 2004; 61: 680.
23. Calabrese JR, Bowden CL, Sachs G, Yatham LN, Behnke K, Mehtonen OP, Montgomery P, Ascher J, Paska W, Earl N, DeVeaugh- Geiss J, Lamictal 605 Study Group: A placebo- controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Clin Psychiatry 2003; 64: 1013-1024. (Pubitemid 37158246)
24. Calabrese JR, Shelton MD, Rapport DJ, Youngstrom EA, Jackson K, Bilali S, Ganocy SJ, Findling RL: A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. Am J Psychiatry 2005; 162: 2152-2161.
25. Findling RL, McNamara NK, Youngstrom EA, Stansbrey R, Gracious BL, Reed MD, Calabrese JR: Double-blind 18-month trial of lithium versus divalproex maintenance treatment in pediatric bipolar disorder. J Am Acad Child Adolesc Psychiatry 2005; 44: 409-417.
26. Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, Koukopoulos A, Cassano GB, Grunze H, Licht RW, Dell'Osso L, Evans AR, Risser R, Baker RW, Crane H, Dossenbach MR, Bowden CL: Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12- month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 2005; 162: 1281-1290.
27. Hadjipavlou G, Mok H, Yatham LN: Pharmacotherapy of bipolar II disorder: a critical review of current evidence. Bipolar Disord 2004; 6: 14-25.
28. Rybakowski J: Long-term pharmacological treatment of bipolar disorders. Neuro Endocrinol Lett 2007; 28(suppl 1):71-93.
29. Fountoulakis KN, Grunze H, Panagiotidis P, Kaprinis G: Treatment of bipolar depression: an update. J Affect Disord 2008; 109: 21-34.
30. Fountoulakis KN, Vieta E: Treatment of bipolar disorder: a systematic review of available data and clinical perspectives. Int J Neuropsychopharmacol 2008; 11: 999-1029.
31. Beynon S, Soares-Weiser K, Woolacott N, Duffy S, Geddes JR: Pharmacological interventions for the prevention of relapse in bipolar disorder: a systematic review of controlled trials. J Psychopharmacol 2009; 23: 574-591.
32. Dunner DL, Stallone F, Fieve RR: Lithium carbonate and affective disorders. 5. A double- blind study of prophylaxis of depression in bipolar illness. Arch Gen Psychiatry 1976; 33: 117-120.
33. Prien RF: NIMH report. Five-center study clarifies use of lithium, imipramine for recurrent affective disorders. Hosp Community Psychiatry 1984; 35: 1097-1098.
34. Prien RF, Caffey EM Jr, Klett CJ: Prophylactic efficacy of lithium carbonate in manicdepressive illness. Report of the Veterans Administration and National Institute of Mental Health collaborative study group. Arch Gen Psychiatry 1973; 28: 337-341.
35. Prien RF, Klett CJ, Caffey EM Jr: Lithium carbonate and imipramine in prevention of affective episodes. A comparison in recurrent affective illness. Arch Gen Psychiatry 1973; 29: 420-425.
36. Prien RF, Kupfer DJ, Mansky PA, Small JG, Tuason VB, Voss CB, Johnson WE: Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination. Arch Gen Psychiatry 1984; 41: 1096-1104.
37. Deshauer D, Fergusson D, Duffy A, Albuquerque J, Grof P: Re-evaluation of randomized control trials of lithium monotherapy: a cohort effect. Bipolar Disord 2005; 7: 382-387.
38. Vieta E, Carné X: The use of placebo in clinical trials on bipolar disorder: a new approach for an old debate. Psychother Psychosom 2005; 74: 10-16.
39. Uhlenhuth EH, Matuzas W, Warner TD, Thompson PM: Growing placebo response rate: the problem in recent therapeutic trials? Psychopharmacol Bull 1997; 33: 31-39.
40. Cipriani A, Pretty H, Hawton K, Geddes JR: Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry 2005; 162: 1805-1819.
41. Nolen WA, Weisler RH, Neijber A, Hellqvist A, Paulsson B: Quetiapine or lithium versus placebo for maintenance treatment of bipolar I disorder after stabilization with quetiapine. 17th Eur Congr Psychiatry, Lisbon, January 24-28, 2009.